In This Issue

CDID Division Officers … Page 1
Tips for successful submission to the AACC Annual meeting … Page 2-3
AACC Annual Meeting 2017: CDID Activities … Page 3-5
2017 Annual meeting: Special events … Page 5
2017 Annual meeting: Sessions recommended to CDID members … Page 6-12

CDID Division Officers

Chair
Gabriella Lakos, MD, PhD, Inova Diagnostics, Inc.

Chair elect
Melissa Rosemary Snyder, Mayo Foundation

Past Chair
Stanley J. Naides, Quest Diagnostics Nichols Institute

Secretary
Tara Sheree Givens, Quest Diagnostics Nichols Institute

Education Coordinator
Maria Alice Vieira Willrich, Mayo Clinic

Professional Development Officer
Thomas E. Burgess, Quest Diagnostics

Staff Liaison
Erin Grady, AACC

The executive committee welcomes three new officers for the year 2017-2018

Treasurer
Peter Martis, Inova Diagnostics

Research Officer
Lokinendi V. Rao, Quest Diagnostics

Communications Officer
Mohammad A Al-Ghoul, Center for Disease Detection, LLC
Tips for successful submission to the AACC Annual meeting

Steven Binder  
Senior Director, Technology Development  
Bio-Rad Laboratories

Many AACC members look forward to the rich menu of educational sessions at the Annual Meeting. But given the breadth of AACC members’ interests, there is not always a large selection of offerings on the program that cater to the tastes of CDID members. As a result, our division works hard every year to develop proposals for sessions that will highlight clinical and diagnostic immunology. The comments below may help division members develop programs sessions that will gain the support of the organizing committee and find a place in the program.

At the highest level, I would comment that proposers often focus their efforts on the quality of the content, whereas the organizing committee gives a lot of consideration to the quality of the audience experience. Above all, who is likely to attend? A session that addresses latest technical advances but covers a very specialized topic may interest a very thin slice of the membership. There are many submitted proposals every year, and topics with broader appeal are more likely to be considered than topics with a very limited audience. If a proposed session is listed as “advanced”, this also might suggest that the audience will be limited. Second, who are the speakers? No one likes to spend 2-3 hours listening to speakers that are dull, unprepared, bring poor visuals etc. So evidence of speaker quality is very important. A prior successful speaking engagement at the AACC offers the most convincing evidence of quality. Other evidence of quality might include presentations at other major meetings and YouTube talks.

Of course the topic of the proposal is extremely important. Above all, the title and the objectives of the session should be readily understandable to any potential attendee. Since many clinical chemists have limited daily experience with immunology, topics that cover more common testing areas are more widely understood—but we can’t talk about hypothyroidism every year. A topic that brings new information to the attendees, especially if not addressed at meetings in the past 1-2 years, is a good starting point. Also, there is a stated focus for each AACC meeting, and it is worth paying attention to these focus areas and identifying topics that connect with these focus areas.

Starting planning efforts well in advance of the submission deadline helps in many ways. First, the proposer is expected to have a firm commitment from the speakers. This is usually not an overnight process. Second, endorsements from other divisions or organizations can improve the likelihood of acceptance (also not an overnight process).
Finally, a review of the sessions from the previous years may offer useful information about educational objectives and topic descriptions that will help the proposer communicate the value of the session. Every word in the submission will be carefully reviewed by the reviewing group, so it is important to follow the instructions, and it is worth the extra effort to polish the text using advice from colleagues and the CDID leadership.

Hopefully these comments will help bring more clinical and diagnostic immunology content to future meetings.

1. CDID ACTIVITIES

**Short Course / Symposia ($0.00)**

*The Complement System: Overview and Laboratory Testing --- Short Course – 72412*, Monday July 31, 2017, 12:30 – 2:00 PM

Ashley Frazer-Abel, Ph.D., University of Colorado School of Medicine
Understanding Complement in the Clinical Laboratory

Maria Alice Willrich, PhD, Mayo Clinic, Moderator
Complement Testing Overview and Interpretation for the Clinical

*Serum Protein Electrophoresis Reporting: New Consensus Guidelines, Interactive Cases, and Interferences --- Symposia – 33217*, Tuesday August 1, 2017, 2:30 PM – 5:00 PM

Ronald Booth, PhD, The Ottawa Hospital, Moderator
2017 Consensus Recommendations for Protein Electrophoresis Reporting

Chris McCudden, PhD, The Ottawa Hospital
Interactive Serum Protein Electrophoresis Case Reporting: A Step Towards Standardization and Synoptic Reporting

David Keren, MD, The University of Michigan Medical School
Challenges in Measuring Monoclonal Proteins Ronald Booth, PhD
Diseases of the Gastrointestinal System: Immune-Mediated and Infectious --- **Symposia – 33213**, Tuesday August 1, 2017, 2:30 PM – 5:00 PM

*Melissa Snyder, PhD, Mayo Clinic, Moderator*

*Autoimmune Gastrointestinal Diseases*

*Amy Leber, PhD, Nationwide Children's Hospital*

*Infections of the Gastrointestinal System*

*Bruce Lanser, MD, National Jewish Health*

*Diagnostic Challenges for Food Allergies*

**Clinical and Laboratory Aspects of Monoclonal Antibody Therapeutics --- Short Course – 74102**, Wednesday August 2, 2017, 10:30 AM – 12:00 PM

*Melissa Snyder, PhD, Mayo Clinic, Moderator*

*Assessment of Monoclonal Antibody Therapeutics and Anti-Drug*

*Maria Alice Willrich, PhD, Mayo Clinic*

*Monoclonal Antibody Therapeutics as Potential Interferents on Protein Electrophoresis and Related Tests*

**Antiphospholipid Syndrome: Clinical Presentation and Laboratory Investigation --- Symposia – 34105**, Wednesday August 2, 2017, 10:30 AM – 12:00 PM

*Anita Rajasekhar, MD, MS, University of Florida*

*Antiphospholipid syndrome: Clinical Presentation and Treatment*

*John Mitsios, Ph.D., BioReference Laboratories, Moderator*

*Antiphospholipid Syndrome: Laboratory Investigation*
CDID Mixer – Reception and Awards Presentation

Tuesday August 1, 2017, 5:30 - 7:00
Marriott Marquis San Diego Marina
The CDID mixer will be joined with the Hematology and Coagulation Division

CDID Mixer is open to all CDID Members

CDID Executive Committee Meeting

Following the CDID mixer

Best Abstract Award Winner: Congratulations to Lusia Sepiashvili PhD, Mayo Clinic


CDID Poster Walk

Tuesday at 12:00 PM

CDID Poster Walk will be a guided discussion on selected posters, open to all attendees.

Tour leader: Maria Alice Willrich, PhD, Mayo Clinic

2. SPECIAL EVENTS

- AACC Community Opening Mixer at the Marriott Marquis San Diego Marina, Sunday, July 30 from 6:45 to 8 pm

- SYCL Workshop and Mixer Developing an Influential Leadership Role for Laboratory Professionals at the Marriott Marquis San Diego Marina Saturday, July 29, 1–5:30 p.m. (Mixer 6–8 p.m.)
3. SESSIONS RECOMMENDED TO CDID MEMBERS

Monday July 31, 2017

Morning Symposia (10:30 AM – 12:00 PM) – cost = $ 0.00

32104
Clinical Endocrine Assays: What Endocrinologists Will Ask You

Carole Spencer, PhD, University of Southern California
Differentiated Thyroid Cancer Tumor Markers

Martin Bidlingmaier, MD, Ludwig-Maximilians University
Insulin-Like Growth Factor I (IGF-1) Assays

Stan Van Uum, MD, PhD, Western University
Measurement of Hair Cortisol: What Can It Tell Us?

32109
Clinical Chemistry’s Hot Topics of 2017
David Morrow, MD, Brigham and Women’s Hospital, Harvard Medical School
Impact of hs-cTn on The Practice of Cardiovascular Medicine

Geoffrey Ginsburg, MD, PhD, Duke University
Successes and Challenges of Omics in Cardiovascular Medicine

Afternoon Symposia (2:30 PM – 4:00 PM)

32221
The Role of the Laboratorian and Clinician in the Diagnosis and Management of Tuberculosis

Joan-Miquel Balada-Llasat, PharmD, PhD, The Ohio State University Wexner Medical Center
Why and When: Selecting the Best Tuberculosis Diagnostic Test
Shu-Hua Wang, MD, MPH, PharmD, The Ohio State University Wexner Medical Center
Combating Tuberculosis in The US and Developing Countries

**Brown Bag July 31, ($25:00)**

42106, 7:30 – 8:30 AM and 52206, 12:30 -1:30 PM

**Immunoglobulin Paraprotein Interference with Chemistry Assays**

Lu Song, PhD, University of California, Los Angeles Medical Center

42107, 7:30 – 8:30 AM and 52207, 12:30 -1:30 PM

**Prognostication of Heart Failure: Perspectives from Transforming Growth Factors (TGF) Super-Family Members**

Damien Gruson, PhD, Cliniques Universitaires Saint Luc

42113 7:30 – 8:30 AM and 52213, 12:30 -1:30 PM

**Anti-Mullerian Hormone (AMH): an Emerging Biomarker for the Assessment of Reproductive Function**

Alicia Algeciras-Schimnich, PhD, Mayo Clinic

42115 7:30 – 8:30 AM and 52215, 12:30 -1:30 PM

**Perils of Hemoglobin A1c Assays: Hidden Hemoglobinopathies, A Case Based Approach**

Sydney Strickland, PhD, University of Virginia School of Medicine

42122 7:30 – 8:30 AM and 52222, 12:30 -1:30 PM
The CDC Lipids Standardization Programs – Ensuring The Quality of Clinical Chronic Disease Biomarker Measurements

Uliana Danilenko, PhD, Centers for Disease Control and Prevention

42124 7:30 – 8:30 AM and 52224, 12:30 -1:30 PM

Leadership Strategies: Cultivating Engagement through Leadership

Cherie Petersen, BA, ARUP Laboratories

Tuesday August 1, 2017

Morning Symposia (10:30 AM – 12:00 PM) – cost = $ 0.00

33220

Biomarkers of Heart Failure with Preserved Ejection Fraction

Garrick Stewart, MD MPH, Brigham and Women's Hospital, Harvard Medical School
Heart failure with preserved ejection fraction: Pathophysiology of an Emerging Epidemic

Petr Jarolim, MD, PhD, Brigham & Women's Hospital, Harvard Medical School, Moderator
What Do Natriuretic Peptides Tell Us in Heart Failure With Preserved Ejection Fraction

David Morrow, MD, Brigham and Women's Hospital, Harvard Medical School
Beyond BNP: Biomarkers in HFpEF and the Pursuit of Personalized Medicine
Afternoon Symposia (2:30 PM – 4:00 PM)

33221
The Role and Utility of Glycated Proteins: Beyond Hemoglobin A1c

David Sacks, MD, MB, ChB, FRCPath, National Institutes of Health
Technical Challenges and Progress in The Measurement of Chronic Glycemia

Cyrus Desouza, MBBS, University of Nebraska Medical Center
Is There a Clinical Need for Fructosamine or Glycated Albumin?

Paul Thornalley, PhD, University of Warwick
Advanced Glycation End-Products: Do They Have A Role in Diabetes?

Brown Bag August 1, 2017

43113 7:30 – 8:30 AM and 53213, 12:30 -1:30 PM
The CDC Hormone Standardization (HoSt) Program: Improving Clinical Measurements of Testosterone and Estradiol

Krista Poynter, BS, Centers for Disease Control & Prevention

43109 7:30 – 8:30 AM and 53209, 12:30 -1:30 PM
Serum Free Light Chains (sFLC): Advantages and Disadvantages of Currently Available Assays

Nicole White-Al Habeeb, PhD, University of Toronto
Wednesday August 2, 2017

Afternoon Symposia (2:30 PM – 5:00 PM)

34213
High-Sensitivity Cardiac Troponin: As With Every New Tool, There is A Learning Curve

Richard Body, PhD, Manchester Royal Infirmary
Debate on European Society of Cardiology (ESC) New Guidelines to Rule-in and Rule-out Acute Myocardial Infarction (AMI) in The Emergency Department (ED) - European Point of View from the ED

Martin Than, MBBS, Christchurch Public Hospital
Debate on European Society of Cardiology (ESC) New Guidelines to Rule-in and Rule-out Acute Myocardial Infarction (AMI) in the Emergency Department (ED) - Non European Point of View from the ED

Peter Hickman, PhD, MD, ACT Pathology
Why Your Cardiac Troponin 99th Percentile Cutoff is Wrong?

Pete Kavsak, PhD, Juravinski Hospital and Cancer Centre, Moderator
Why Your Cardiac Troponin Result is Wrong?

Brown Bag Aug 02, 2017

44111 7:30 – 8:30 AM and 54211, 12:30 -1:30 PM

The CDC Vitamin D Standardization-Certification Program (VDSCP): Improving the Clinical Measurement of Total 25-Hydroxyvitamin D
Otoe Sugahara, BS, Centers for Disease Control and Prevention

44114, 7:30 – 8:30 AM and 54214, 12:30 -1:30 PM

**Sepsis Biomarkers and the Role of the Laboratory**

Angela Fung, PhD, University of Toronto

44123, 7:30 – 8:30 AM and 54223, 12:30 -1:30 PM

**Testing for Alpha 1-Antitrypsin Deficiency**

Joshua Bornhorst, PhD, Mayo Clinic

44128 7:30 – 8:30 AM and 54228, 12:30 -1:30 PM

**Biotin-Related Interference with Immunoassay Methodologies**

Randal Schneider, PhD, Abbott Diagnostics

44101, 7:30 – 8:30 AM and 54201, 12:30 -1:30 PM

**Thyroid Function and Laboratory Assessment of Thyroid Disease.**

David Kemble, PhD, Dartmouth-Hitchcock Medical Center

44110, 7:30 – 8:30 AM and 54210, 12:30 -1:30 PM

**Natriuretic Peptides: Testing BNP and NT-proBNP with Neprilysin Inhibitors**

Sean Campbell, Ph.D, University of Virginia Health System
University

191006
7/30/2017 10:30AM - 12:00PM ($180.00)

Making your Core Lab Safe from Ebola and Zika

Bonny Van, PhD, LifeOmic, Moderator
Assembling a Biosafety Toolkit to Keep Your Lab Safe

Michael Pentella, PhD, University of Iowa
State Public Health Laboratory as Resource for Biosafety

James Snyder, PhD, University of Louisville
Bad Bugs Don't Stay in the Micro Lab

Kidney Disease – Laboratory Testing Makes a Difference

Graham Jones, DPhil, MBBS, St Vincent's Hospital (SydPath)
Optimizing eGFR Use and Interpretation

David Seccombe, MD, PhD, CEQAL
Mobile Screening Programs For Early Detection of CKD

Christine Collier, PhD, Kingston General Hospital & Queen's University, Moderator
CKD - What's New? eGFR Rate of Change and KFRe

John Kellum, MD, University of Pittsburgh School of Medicine
AKI - Zoom Ahead 5 Years!